Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00914589 · ClinicalTrials.gov registry record · Phase 2
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
A Phase 2 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 479
- Enrollment target
NCT00914589 is a Phase 2 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 479 participants.
The verdict
NCT00914589, a Phase 2 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 479 participants
- Enrollment target
Study Summary
This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
Interventions
- DRUG placebo
- DRUG catridecacog
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 479 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00914589
The ClinicalTrials.gov registry entry for NCT00914589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00914589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00914589 about?
NCT00914589 is a clinical study titled "Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery". This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
What is the current status of trial NCT00914589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 479 participants. The study started on 2009-07. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00914589?
The interventions under investigation include: placebo (DRUG), catridecacog (DRUG).
Who is sponsoring clinical trial NCT00914589?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.